Aug 27, 2009 | Seattle Post-Intelligencer
Par Pharma edges higher to finish weekly gains
Shares of Par Pharmaceutical Cos. continued to rise Friday, capping a week where the company won a patent challenge that could allow it to start selling a generic version of a pain drug, and won FDA approval of a generic blood pressure patch.
Par Pharma edges higher to finish weekly gains
Shares of Par Pharmaceutical Cos. continued to rise Friday, capping a week where the company won a patent challenge that could allow it to start selling a generic version of a pain drug, and won FDA approval of a generic blood pressure patch.
Par Pharmaceutical & Aveva Drug Delivery Systems Receive Final...
Par Pharmaceutical Companies, Inc. today announced that its licensing partner, Aveva Drug Delivery Systems, has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for a clonidine transdermal system.
Also on Topix